NCT03953456终止2 期
A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) Treatment Administered Once Daily on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Genfit
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Change in relative amount of saturated fatty acids in the liver
研究概览
简要总结
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks of treatment with a 4-week wash-out period. This study will achieve mechanistic information about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
The Investigator, subject, and study personnel will be blinded to the treatment.
Identification numbers will be assigned to a subject at the Screening Visit. Upon completion of the Screening Visits, eligible subjects will be randomly assigned to Sequence Group A or Group B, defining the order of treatments.
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or post-menopausal females aged from 40-75 years inclusive at first Screening Visit. (Post-menopausal defined as: subject should be surgically sterilized at least 6 months or no spontaneous menses for at least 1 year prior to screening)
- •Must provide signed written informed consent and agrees to comply with the study protocol.
- •Liver fat percentage ≥ 5 percent (as measured with Magnetic Resonance Spectroscopy)
- •25.0 ≤ BMI ≤ 38.0 kg/m^2
- •Stable dietary habits and physical activity pattern (over 3 months prior to Screening Visit)
- •Subject agrees not to change dietary habits and physical activity pattern, to follow diet and lifestyle recommendations and not to consume or use illicit drugs during the study up to end of treatment.
排除标准
- •Medical history:
- •Documented weight loss of more than 5 percent during the 6-month period prior to Screening Visit
- •Contra-indications for magnetic resonance imaging / spectroscopy
- •Known history of Type 1 and 2 diabetes
- •Known chronic heart failure (Grade I to IV of New York Heart Association classification)
- •History of clinically significant acute cardiac event within 6 months prior to Screening Visit such as: stroke, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures)
- •Uncontrolled hypertension despite optimal antihypertensive therapy
- •Other well documented causes of chronic liver disease according to standard diagnostic procedures.
- •Symptoms of clinical depression
- •Other concurrent medical (e.g., immunological, neoplastic, endocrine, hematological, gastrointestinal or neurological) or psychiatric condition, which, in the opinion of the Investigator, would place the subject at increased risk, preclude obtaining voluntary consent/assent or compliance with required study procedures, or would confound the objectives of study
- •Known hypersensitivity to the investigation product or any of its formulation excipients
- •Concomitant medications and lifestyle:
- •Fibrates are not permitted from 8 weeks before Screening up to end of treatment. Subjects taking statins or ezetimibe prior to Screening Visit 1 may participate if the dose has been stable for 3 months prior to Screening Visit 1 and no dose adjustments are anticipated
- •Currently taking drugs that can induce steatosis/steatohepatitis including, but not restricted to: corticosteroids (parenteral & oral chronic administration only), amiodarone (Cordarone), tamoxifen (Nolvadex), and methotrexate (Rheumatrex, Trexall), which are not permitted 30 days prior to Screening and up to end of treatment
- •Subjects receiving thiazolidinediones (glitazones [pioglitazone, rosiglitazone])
- •Currently taking any medication that could interfere with study medication absorption, distribution, metabolism, or excretion or could lead to induction or inhibition of microsomal enzymes, e.g., indomethacin, which are not permitted from Randomization until end of treatment
- •Any medication use known to interfere with glucose homeostasis/metabolism
- •Current or recent history (<5years) of significant alcohol consumption. For men, significant consumption is typically defined as higher than 30 g pure alcohol per day. For women, it is typically defined as higher than 20 g pure alcohol per day
- •Subjects who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the month following the end of the study
- •Is participating in any other study and have received any other investigational drug or device within 30 days prior to Screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with study compliance or outcome assessments
- •Subjects who cannot be contacted in case of emergency
- •In addition to the above criteria, subject should not present any of the following biological exclusion criteria:
- •Positive anti-human immunodeficiency virus (HIV) antibody
- •Positive hepatitis B surface antigen
- •Positive hepatitis C Virus (HCV) antibody
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >5 x upper limit of normal (ULN)
- •Conjugated bilirubin > 1.50mg/dL due to altered hepatic function Note: Gilbert Disease subjects are allowed into the study
- •International normalized ratio >1.40 due to altered hepatic function
- •Platelet count <100,000/mm^3 due to portal hypertension
- •Serum creatinine levels >1.53 mg/dL in males and >1.24 mg/dL in females
- •Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as subjects with markers of kidney damage or estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m^2)
- •Unexplained serum creatine phosphokinase (CPK) >2 x ULN. In case of explained elevated CPK >2 x ULN, the measurement can be repeated prior to Randomization. In this case, retest should be performed within 1 to 2 weeks after initial test. A CPK retest >2 x ULN leads to exclusion
- •Hemoglobin A1c (HbA1C) > 6.4% and/or fasting plasma glucose (FGP) > 126 mg/dl
研究组 & 干预措施
elafibranor 120mg followed by placebo
Experimental
Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
干预措施: elafibranor 120mg (Drug)
elafibranor 120mg followed by placebo
Experimental
Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
干预措施: Placebo (Drug)
placebo followed by elafibranor 120mg
Placebo Comparator
Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
干预措施: elafibranor 120mg (Drug)
placebo followed by elafibranor 120mg
Placebo Comparator
Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Change in relative amount of saturated fatty acids in the liver
时间窗: After 6 weeks
Relative amount of saturated fatty acids (SFA) in the liver measured by Magnetic Resonance Spectroscopy (1H-MRS) at the end of 6 weeks treatment period
次要结局
- Incidence and severity of treatment emergent adverse events (TEAEs) and their relationship to study drug(After 6 weeks)
- Change in hepatic insulin sensitivity(After 6 weeks)
- Glucose homeostasis markers(After 6 weeks)
- Lipid metabolism markers(After 6 weeks)
- Inflammatory markers(After 6 weeks)
- Liver function(After 6 weeks)
- Renal function(After 6 weeks)
- Body weight(After 6 weeks)
- Body Mass Index(After 6 weeks)
- Waist circumference(After 6 weeks)
- Incidence of clinically meaningful changes from baseline in safety laboratory parameters, and vital signs(After 6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Baclofen/Diazepam Supps for Treatment of Pelvic Floor MyalgiaPelvic Floor DyssynergiaNCT03427216Dr. John A. Thiel Medical Professional Corporation60
尚未招募
不适用
Crossover Study of the PD of ENA-001 and hypoxia.Respiratory impairmentNL-OMON24789Enalare Therapeutics12
已完成
1 期
Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy VolunteersQT/QTc Interval in Healthy VolunteersNCT03554304Wockhardt60
招募中
不适用
The effects of atomoxetine on brain potentials in response to auditory distracting sounds during driving in adults with attention-deficit hyperactivity disorder.ADHD, atomoxetine, electroencephalography (EEG), event-related potential (ERP), attention, inhibitionNL-OMON24935trecht UniversityFaculty of ScienceDepartment of Psychopharmacology30
已完成
2 期
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSAObstructive Sleep ApneaExcessive SleepinessNCT02806895Jazz Pharmaceuticals34